McLaughlin PJ, et al. - In this investigation, researchers tested the safety and effectiveness of a proprietary new eye drop formulation for the topical treatment of dry eye disease (DED), a prevalent complication of diabetes and presents as reduced tear production and/or increased corneal surface sensitivity often with secondary ocular surface changes. To study the effectiveness and safety of the investigational compound that contained 20 μg/ml of naltrexone (NTX), type 1 diabetes (T1D) was established in male Sprague-Dawley rats. The data presented in this work showed a new eye drop of 20 μg/ml NTX effectively reversed tear film deficits and restored corneal surface sensitivity in diabetic animals without toxic side effects. After 30 days of treatment, safety studies in naïve rats and rabbits revealed no visible ocular pathology.